For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG-ACRIN EA2182

Trial Overview

Official Title

Study Lower-Dose Chemoradiation for Early-Stage Anal Cancer

Study Purpose

To compare lower-dose chemoradiation therapy to standard-dose chemoradiation therapy and to find out if this approach is better or worse than the usual approach for anal cancer.

Diagnosis

Anal Cancer

Eligibility

Patients can be HIV-positive or HIV-negative.

Patients must have no history of prior radiation or chemotherapy for this malignancy.

Patients must not have had a potentially curative surgery for this cancer prior to enrolling in this study.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Study Treatment: Chemoradiation, which is when you receive both chemotherapy and radiation
  • Group 1: Standard dose of chemoradiation therapy
  •  Group 2: Lower dose of chemoradiation therapy
  • Quality of Life questionnaires
  •  Patients must keep a pill diary.

After completion of chemoradiation therapy, patients will be followed for up to 5 years and watch for side effects, monitor cancer, and complete questionnaires.

For more information, visit ClincialTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase II
Methodist Health System Trial Code
EA2182
Related Specialties